Working as a Team for Cardiovascular Risk Reduction in Patients With T2D

2008 FDA Guidance

First Antihyperglycemic Agent to Show a CV Benefit -- Empagliflozin

Data on Canagliflozin and Other SGLT2 Inhibitors

GLP-1 Receptor Agonists Have Also Shown CV Benefit

CVOT Data on Other GLP-1 Receptor Agonists

Upcoming CVOT Data

Common Adverse Events

Diabetes Drug Label Updates for Reduction of CVD Death

Clinical Application for Primary Care, Endocrinology, and Cardiology

Viewpoint From a Diabetologist/Endocrinologist

Viewpoint From a Cardiologist

How Endocrinology and Cardiology Can Work Together for Improved Patient Outcomes

Abbreviations